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Functional magnetic resonance imaging investigation of the
amphetamine sensitization model of schizophrenia in healthy
male volunteers
Abstract
These transient load-dependent abnormalities of frontal and temporal activity induced by amphetamine
sensitization support neuroimaging findings in schizophrenic patients, implying that amphetamine
sensitization may help to bridge pathophysiological theories of schizophrenia that focus on
pharmacological (dopaminergic) and cognitive mechanisms, respectively.
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Abstract 
Context: Recent work suggests that the amphetamine sensitisation model of schizophrenia can 
safely be induced in healthy volunteers, and is associated both with behavioural and 
dopaminergic hypersensitivity to amphetamine. However, the effects of a sensitisation on brain 
function remain unclear. 
 Objective:  To assess the impact of a sensitising dosage regimen of dextroamphetamine on 
human cortical functioning and cognition. 
Design: Randomised, double-blind, parallel-groups design using pharmacological functional 
magnetic resonance imaging. 
 Setting: The neuroimaging research unit at the Institute of Psychiatry (KCL), UK 
Participants:  Healthy Male Volunteers (n =22) 
Interventions : Dextroamphetamine (20mg) or a Placebo on 4 testing sessions, using a  dosage 
regimen shown to induce sensitisation (i.e. 3 doses administered with a 48hr inter-dose interval 
and a final dose after a 2-week wash-out period). 
 Main Outcome Measures: Sensitisation was characterised by enhanced subjective response to 
the drug, changes in behavioural performance (reaction time and accuracy) and fMRI 
measurements of brain activity during an N-Back working memory task. 
 Results: Sensitisation was associated with more rapid responding during the performance of an 
intermediate-load working memory challenge. During a high-load cognitive challenge, 
sensitisation did not produce performance deficits, but fMRI showed hyperactivity of dorsolateral 
prefrontal cortex (DLPFC) and aberrant recruitment of the superior temporal gyrus, caudate 
nucleus and thalamus. Furthermore, the change in striatal activity was negatively correlated with 
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the enhanced subjective effects of the drug, whereas prefrontal hyperactivity was positively 
correlated with sensitised measures of alertness. 
 Conclusions: These transient load-dependent abnormalities of frontal and temporal activity 
induced by amphetamine sensitisation support neuroimaging findings in schizophrenic patients 
implying that amphetamine sensitisation may help to bridge pathophysiological theories of 
schizophrenia that focus on pharmacological (dopaminergic) and cognitive mechanisms, 
respectively.  
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Introduction 
Patients with schizophrenia, and those with stimulant induced psychosis, commonly display 
stress-hypersensitivity and a profoundly reduced threshold for the psychotogenic action of 
stimulant drugs 1-7.  These effects have been linked to enhanced drug-induced striatal dopamine 
release 8-10. Rodents receiving repeated intermittent amphetamine exposure display a similar 
“sensitisation” to stress11, 12, to the psychomotor stimulatory effects of the drug 13-19 and to the 
elevation of striatal dopamine levels20. Thus, amphetamine sensitisation in rodents is used to 
model some aspects of schizophrenia.  
It is well established that patients with schizophrenia suffer from significant cognitive deficits in 
various domains, including working memory, executive control, attention, affective processing 
and learning21-23. This is a challenge for the amphetamine sensitisation model in rodents because 
while sensitisation does alter some aspects of rodent function, including prepulse and latent 
inhibition24, 25, attentional set-shifting26, 27 there is little evidence that sensitised rodents display 
deficits in, for example in working memory where patients are severely impaired26, 28, 29. In 
contrast, sensitised primates do display profound deficits  in spatial delayed response (a test of 
spatial working memory) linked to reduced dopamine turnover in the cortex30 in addition to a 
complex set of aberrant behaviours more akin to schizophrenia30-32, including hyper-vigilance, 
hallucinatory-like activity. In general, the literature shows that the amphetamine model of 
sensitisation replicates a proportion of the cognitive deficits associated with schizophrenia.   
In the cortex, dopamine signalling within a narrow “optimal” range enhances cortical efficiency33-
35, acting to reduce physiological noise and enhancing signal-to-noise ratio (SNR) for salient or 
sustained prefrontal cortical inputs36, 37. Notably, both over- and under-stimulation of cortical D1 
receptors are equally detrimental to cognitive performance. It has been suggested that a reduction, 
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rather than an excess, in prefrontal cortical dopamine signalling gives rise to the cognitive 
dysfunction seen in patients38, 39. However, the compensatory upregulation of cortical D1 
receptors seen in patients38 would also render patients hypersensitive to drug- or stress-related 
elevation of cortical dopamine40. Following amphetamine administration, healthy controls 
homozygous for the Val158Met polymorphism of the Catechol-O-Methyl-Transferase (COMT) 
gene display a similar pattern of relatively inefficient prefrontal recruitment (i.e. hyperactivity to 
maintain the same performance level) during a high-load working memory task41. This effect is 
reminiscent of frontal and striatal hyperactivity seen in patients with schizophrenia during a 
similar task42, 43. 
Beyond cognitive performance, DLPFC hyperactivity is also seen in acutely psychotic patients44, 
45 and in healthy volunteers following the administration of hallucinogenic agents46-49 suggesting 
that this cortical region plays an important role in the genesis of psychosis50. Indeed, while 
prefrontal lesions block behavioural (locomotor) sensitisation in rodents, such ablation in 
primates impedes only the sensitisation of hallucinatory-type behaviour and in fact enhances 
psychomotor sensitisation51. Such findings suggest important between-species differences in 
prefrontal function and, implicitly, fronto-striatal connectivity, with particular respect to the 
expression of psychosis-like behaviours52.  
Contemporary cognitive models of schizophrenia emphasise the importance of disrupted cortico-
cortical integration (e.g. fronto-temporal dysconnectivity)53-57 over dopamine dysregulation in the 
development of psychotic symptoms58. A central challenge for the field is to marry 
pharmacological and cognitive perspectives of the disorder.  For example, dopaminergic 
medication can partially normalise abnormal frontal activity59, 60, and recent pathophysiological 
theories of schizophrenia emphasise the importance of dopamine-dependent regulation of 
synaptic plasticity61-63.  Thus, dopamine-sensitive cortical circuits represent attractive targets for 
translational modelling using amphetamine sensitisation. Recently, both behavioural (eye-blink) 
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and neurochemical sensitisation of striatal dopamine has been robustly demonstrated in healthy 
volunteers64. However, in contrast to the extensive animal literature, a neurophysiological 
examination of the effects of amphetamine sensitisation on brain function in humans is still 
lacking.  Here we explore the effects of a sensitising regimen of amphetamine on brain activity 
during a working memory (WM) task using language stimuli (letters). Given the extensive 
literature on schizophrenic abnormalities in fronto-temporal areas during language processing53-57 
and in fronto-striatal circuitry during executive control processes like WM42, 65, we put a 
particular emphasis on prefrontal cortex, striatum and temporal cortex, which were used as 
regions of interest in our fMRI analyses. Explicitly, we test the hypothesises that a) repeated 
placebo administration will not be associated with any significant changes in cortical functioning, 
b) a sensitising regimen of amphetamine will lead to reduced efficiency in cortical function, 
evident as increased prefrontal activity at the high-load condition41 c) This prefrontal dysfunction 
will be associated with dysregulation of the temporal ipsilateral lobe 
 
 
Methodology 
Twenty-two right handed male volunteers (age 30.8 years +/- 8.5 years), were recruited and 
assigned to receive either four oral doses of dexamphetamine (20mg), or four doses of a placebo, 
using the same pattern of amphetamine administration, albeit with a fixed dose across all 
participants, as that employed Boileau et al64. Subjects received the first 3 doses with a 48-hour 
inter-dose interval (Sessions 1-3) and again (4th dose) after a 2 week wash-out period (Session 4) 
using a double-blind procedure. Participants were excluded if they had previous medical history, 
were taking any medications, or had a family history of mental illness or substance abuse 
problems. Furthermore, on each visit a drug-urine analysis was carried out to exclude the use of 
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recreation drugs. Subjects were scanned approximately 120 minutes post-administration during 
sessions 1 (acute exposure) and 4 (repeated/ sensitised exposure) in an effort to model the effects 
of sensitisation-related dopaminergic dysregulation on the neural substrates of working memory. 
Participants additionally performed a rewarded decision making task and an explicit motor 
sequence learning task. The data from these paradigms are not included here, and will be the 
subjects of separate manuscripts. The project was approved by the Institute of Psychiatry 
Research Ethic Committee (REC ref # 022/03). 
Data Acquisition 
Imaging was performed with a 1.5T GE scanner (GE, USA). 180 volumes (matrix size 64x64) 
with whole brain coverage were acquired during each functional run. Each volume comprised 36 
slices, collected in an interleaved manner, with a slice thickness of 3mm, with an additional 
0.3mm gap between slices. The repetition time was 3 seconds, TE = 40ms, flip angle = 900. Total 
acquisition time was 9 minutes (540 seconds). High resolution structural scans were also 
acquired (Spoiled Gradient Recalled (SPGR) and High-Resolution Gradient Echo). 
N-Back Working Memory Task 
While lying in the scanner, subjects performed a standard blocked N-back working memory task 
using visually presented letters 66. This task involved nine alternating 30 second blocks of 
working memory, with four levels of difficulty (N = 0, 1, 2,3). In the control condition (N=0), 
subjects were asked to press the button whenever they saw the letter X. Subjects were informed 
at the start of each 30 second block as to the nature of the response required (N = 0, 1, 2, or 3). 
Stimuli were presented with an ISI of 2000ms. 
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Analysis 
Assessment of sensitisation 
During each visit self-reported subjective drug effects were assessed using the Addiction 
Research Center Inventory (ARCI) for amphetamine67-69, the Profile of Mood States (POMS)70, 
and Visual Analogue Mood Scales71 at baseline and every 60 minutes for 240 minutes. When 
completing these ratings, subjects were asked to score each item for "how they feel at the present 
moment" and the questionnaires were administered hourly. Physiological data including eye-blink 
rate, pulse and blood pressure (BP) were also collected by a the same researcher in the same 
environmental context. Pulse and BP were collected seated following a resting perior of 5min 
using an electronic sphygmomanometer. Eye-blink rate was taken as the average number of 
blinks counted over a 3 minute period while subjects were at rest, participants were not explicitly 
informed when this measure was being collected.  
We expected the expression of behavioural (subjective) sensitisation would mirror previous 
findings64, 72-74.While there is some divergence between the findings of these two groups we 
expected to see enhanced amphetamine-like experience, amphetamine-induced euphoria (ARCI-
MBG), profile of mood states activity-vigor, alertness and attentiveness and positive affect 
(happy-sad). Physiologically we expected resting eye-blink rate would show sensitisation. 
 
For statistical analyses of each dependent variable, a Group x Administration/Day analysis of 
variance (ANOVA) with repeated measures on the second factor was employed. The group factor 
had two levels (amphetamine versus placebo), and administrations had four levels (Day 1, 3, 5 
and 19). The chosen level of significance was p< 0.05 with Greenhouse-Geisser correction. All 
calculations were performed using SPSS12.1 for Windows.   
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Behavioural analyses 
A repeated-measures ANOVA (GROUP x TIME x LOAD) was used to test for any significant 
between-group differences in both performance accuracy (false positives, and misses) and 
reaction time. Additional post hoc paired T-tests were used to test specific hypotheses in the 
amphetamine group. To confirm a relationship between behavioural and subjective sensitisation 
we tested for correlations between both sensitised measures after correcting for individual 
differences in inter-session plasma amphetamine concentration. All calculations were performed 
using SPSS 13 for windows.   
fMRI analysis 
After preprocessing, including realignment, image distortion correction75, 76, and normalization, 
statistical analysis was carried out using the general linear model77, 78 as implemented in 
Statistical Parametric Mapping 2 (SPM2; Wellcome Trust Centre for Neuroimaging, London, 
UK).  Each subject’s EPI data were normalized to a MNI T1 template. Our model coded separate 
regressors for each of the 4 conditions (Control, 1-Back, 2-Back, and 3-Back). The BOLD 
response was convolved with a canonical hemodynamic response function79. The data were high-
pass filtered (cut-off 128s) and corrected for serial correlations using a first-order autoregressive 
model. 
 
At the group level, we performed a random effect analysis. Images of parameter estimates for 
each of the four conditions of interest (N = 0, 1, 2, 3) from the first-level analysis were entered 
into the second level of analysis using two-sample t-tests to compare groups (Placebo Vs 
Amphetamine). Separate 4x2 ANOVAs (F-tests) were used to test for a main effect of time 
(session) and a time-by-condition interaction in each group. Finally, as we expect the 
hypothesised cortical inefficiency to be most apparent during a high-load  working-memory 
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challenge, a paired t-test (within-group Session1 versus Session2 comparison) was used to probe 
the effects of sensitisation during this primary condition of interest (N=3). In the case of 
ANOVAs, contrasts were calculated according to Henson & Penny’s technical note “ANOVAs 
and SPM” (available at http://www.fil.ion.ucl.ac.uk/~wpenny/biblio/Keyword/ ANOVA.html). 
 
Statistical Parametric Maps (SPMs) of the t-statistic were constructed using a generalized 
Greenhouse-Geisser correction. For both F-tests and t-tests, SPMs were thresholded at p<0.05 
following family-wise error (FWE) correction for multiple testing in predefined volumes of 
interest. To test our primary hypothesis regarding the reduction in frontal cortical efficiency, a 
priori regions of interest were defined on the basis of the results of Mattay et al.41, wherein 
amphetamine-induced cortical hyperactivity was seen during high-load cognitive challenge in 
methionine homozygotes for the Val158Met polymorphism of the COMT gene (Met/Met). 
However, as we had no explicit hypothesis regarding laterality of any sensitisation effect, the 
image used for SVC included 15mm spheres covering the left middle frontal gyrus41 and a 
second sphere in the opposite hemisphere. Additionally, the striatum was defined according to 
Mawlawi80. Given the paucity of literature on amphetamine-induced dysregulation of temporal 
lobe activity in healthy controls, a conservatively defined (i.e. large) region of interest including 
the superior temporal gyrus bilaterally, drawn from the Automated Anatomical Labelling 
Toolbox81, was used (see supplementary data). 
 
To establish that changes in BOLD responses were related to sensitisation-related processes, 
rather than simply a consequence of drug tolerance, we tested for correlation between subjective 
measures of sensitisation and the mean signal in the right prefrontal ROI and the anatomically 
defined striatal ROIs. Although at the group level there were no significant differences in mean 
plasma amphetamine levels across the two sessions, suggesting that our group effects did not 
reflect dosage differences. As we had used a standard dose for all subjects, we controlled for 
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individual differences in inter-session plasma amphetamine concentration in these correlational 
analyses (using partial correlation). 
 
Results  
Group-by-Session interactions identified sensitisation-related changes (enhancement confirmed 
with post-hoc t-tests) in both amphetamine-like experiences (ARCI: Amphetamine F(2.5, 49.8) = 
4.15 p< 0.015, see figure 1) . Unlike Boileau et al, but in keeping with findings of Strakowski et 
al. drug-induced euphoria was also sensitised (ARCI: MBG (Euphoria)  F(2.3, 46.3) = 5.13 p<0.009). 
Furthermore, subjective vigour (profile of mood states: activity-vigour; F(2.8, 55.8) =  3.73 p< 0.02), 
Alertness (visual analogue scales: alert-drowsy; F = 4.15; p<0.015)  and the attentiveness (visual 
analogue scales: attentive-dreamy; F(3, 32.4) = 3.99 p<0.02) were also significantly enhanced 
following sensitisation. These effects were relatively robust, and were evident in at least 7 out of 
11 participants in each case. Neither eye-blink rate (F(2.5, 50.9) = 1.49 p<0.63), a commonly 
employed index of psychomotor activity, nor cardiovascular parameters (pulse: F(3, 50) = 1.49, p< 
0.23; blood pressure: F(2.2, 44.4) = 0.18, p< 0.85) were sensitised following repeated amphetamine 
exposure.  
We tested whether task performance was sensitive to group (treatment), session (1st and last 
dosing), or working memory load using a repeated measures 4x2x2 ANOVA for correct 
responses and reaction time and found evidence for a main effect of WM load on task accuracy 
(F(2,41) = 1932.9, p<0.001) and response time (F(2,38) = 32.7, p<0.001). No significant interactions 
were found. However, as we expected sensitisation to be linked with psychomotor stimulation 
only, we tested the corresponding simple main effect and found that the amphetamine group were 
faster on session 4 (post-sensitisation) than on session 1 (acute exposure)  (T(10) =2.398, p<0.0185 
(1-tailed)). Interestingly, the sensitisation of reaction time was most pronounced in the medium 
12 
 
load condition (2-Back) (T(10)= 3.79,  p< 0.002 (1-tailed) see Supplementary Figure 2). 
Importantly, this sensitisation of reaction time during the medium load condition was 
significantly correlated with the sensitisation of the subjective “amphetamine-like” experience 
after correcting for individual differences in plasma amphetamine concentration on the two 
session (as measured by the ARCI score for amphetamine score; partial correlation coefficient of 
-0.727, p<0.009; see Figure 1). Together, these data suggest that there may be a common neural 
substrate for the behavioural and subjectively perceived aspects of sensitisation.  
The fMRI data showed similar load-dependent network during memory performance in both the 
placebo and amphetamine groups (see supplemental material Figure 1 and Tables 1 and 2). No 
significant differences were seen between the placebo and amphetamine groups on day 1 (pre-
sensitisation). Similarly, no main effect of session, or session-by-WM load interaction was seen 
in the placebo group. However, in the amphetamine group, activity in the right superior temporal 
gyrus (STG) showed a significant main effect of time (MNI coordinates [60 -9 6]; p<0.05 
corrected) with activity in this region elevated following sensitisation, compared to the first 
session (acute exposure) (see Table 1 and the high WM-load paired t-test in Table 2). A 
significant interaction between session and WM-load was also evident in the STG in this group, 
although the cluster extended into the operculum and putamen (MNI coordinates [60 -9 6]; 
p<0.007 (see Figure 2 and the lower panel in Table 1). In particular, in the STG BOLD signal 
decreased with greater WM load following acute exposure (day 1), whereas it increased at the 
highest load following sensitisation (see the upper panel of Figure 2).  
We scrutinized this interaction further by testing for a simple main effect of time under high WM 
load, contrasting the effects of amphetamine exposure following sensitisation to those after acute 
exposure. This contrast confirmed a significant increase of BOLD activity within the right STG 
(MNI coordinates [57 -12 12]; p<0.04). The same increase was found in the right DLPFC (MNI 
coordinates [33 48 30]; p<0.02), and there was a trend towards significance within the striatum 
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(MNI coordinates [15 15 9]; p<0.056). As explained in the Methods section, these results were 
based on height-level correction for multiple comparisons within predefined volumes of interest. 
Notably however, all three regions (and an additional two regions within the right hemisphere, 
thalamus and precuneus) survived a whole-brain correction for multiple comparisons at the 
cluster-level (see Figure 3 and supplementary material Table 4).  This amphetamine-induced 
hyperactivity in prefrontal cortex, striatum and thalamus during a high-load WM challenge shows 
striking parallels to previous findings of abnormally high activity in these regions in 
schizophrenic patients performing a similar WM task 42. 
Finally, the increase in prefrontal activity following sensitisation was evident in 10 out of 11 
individual participants. Furthermore, the change in prefrontal BOLD signal was positively 
correlated with the sensitisation of subjective alertness (after controlling for between session 
differences in amphetamine plasma concentration), partial correlation coefficient of 0.657, 
p<0.021 (1-tailed) (see the lower panel of figure 3). The right striatum showed correlation with 
the sensitisation of subjective happiness (VAMS Happy-Sad) although surprisingly it reflected a 
negative relationship;- r = -6.08, p<0.04 (2-tailed); but was at trend significance following 
correction for individual differences in drug concentration; partial correlation coefficient of -6.08, 
p<0.062 (2-tailed).  
 
Discussion 
The sensitisation of subjective measures seen here is in keeping with earlier observations of 
enhanced amphetamine-like experiences, euphoria, happiness, activity-vigour and attentiveness64, 
72-74.  We suggest that the dosage pattern employed here produces a robust sensitisation. This is 
supported by the first demonstration of a functional consequence of experimentally-induced 
sensitisation in humans, i.e. faster cognitive performance. Within the context of the study design 
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it is not possible to determine whether this reaction time effect reflects simple psychomotor 
sensitisation, enhanced motor readiness, attentional processing, or increased motivation to 
perform. However, the lack of faster responding during control and low-load conditions would 
argue against a simple psychomotor speeding.  Furthermore, the lack of significant enhancement 
during the high-load condition suggests that this performance benefit is dependent upon efficient 
prefrontal cortical recruitment.  
When exploring the fMRI data in the amphetamine group, a simple main effect of time contrast, 
across all loads, was associated with increased BOLD signal in the right STG, precuneus, 
rolandic operculum and insula, putamen, cerebellum and a number of areas on the ventral visual 
pathway. We will discuss the STG and precuneus in greater detail below. However as these other 
regions were not predicted a priori it is hard to be definitive about these effects. Nonetheless, the 
evidence for changes in motor networks (i.e. putamen and cerebellum) is consistent the speeding 
of reaction times following sensitisation and the role of dopamine in motor function. 
Furthermore, the enhancement of the ventral visual pathway (i.e. fusiform and inferior temporal 
gyri) could be indicative of enhanced attentional processing following sensitisation. 
 
We also observed a significant load-by-time interaction in right STG and precuneus activity 
during our verbal working memory paradigm (N-Back). The left-lateralised homologues of these 
two regions, in addition to the middle frontal gyrus (DLPFC) and anterior cingulate cortex82, 
subserve verbal fluency performance83. Numerous neuroimaging studies of schizophrenia have 
demonstrated disruption of this network across a number of different paradigms55, 84-87, often in a 
load or state-dependent manner54, 86, 88. Importantly, some evidence suggests that disruption of 
this network, and associated failure to suppress temporal lobe activity in the face of frontal 
hyperactivity, may be linked to elevated cortical dopamine transmission, rather than 
hypodopaminergia59, 60. Further examination has demonstrated a dynamic pattern of effective 
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connectivity within this network during task performance, with the prefrontal cortex modulating 
cingulate function and fronto-temporal connectivity, possibly via the precuneus83. Our findings 
could reflect a similar process in the right hemisphere, where increased cognitive demand might 
lead to failure in recruiting the cingulate and thus an inability to maintain prefrontal cortical 
suppression of the STG.  
 
We failed to identify a significant load-by-session interaction in the DLPFC. This may be due to 
the complex non-linear relationship known to exist between prefrontal neuronal recruitment, 
baseline cortical dopamine levels, task difficulty and performance22, 41, 89. When the high-load 
condition was examined in isolation we found that sensitisation was associated with prefrontal 
hyperactivity, in the absence of any performance deficits. Ten of the eleven participants in each 
group in this study were heterozygous for the Val/Met polymorphism of COMT, and thus 
variation in baseline dopamine due to this polymorphism was theoretically minimised. In 
accordance with this intermittent (Val/Met) phenotype, we found that amphetamine and placebo 
groups showed very little difference in prefrontal activation during session 1 (acute amphetamine 
exposure), with both groups demonstrating a linear recruitment of the prefrontal cortex up to the 
high-load condition, but importantly, neuronal recruitment diminishes as WM capacity was 
exceeded (consistent with the inverted-U load-activity curve). The shifting of this curve to the 
left in patients with schizophrenia is thought to lead to the same hyper-recruitment, followed by 
hypoactivity, at far lower-load cognitive challenges (i.e. hypofrontality). Our findings are 
suggestive of a similar frontal “inefficency” to that seen in patients, albeit with a far smaller 
magnitude more akin the effects of acute amphetamine in Met-Met homozygotes. Thus, the 
cortical effects of sensitisation in humans is to some degree equivalent to that associated with 
gaining a COMT methionine allele (Val/Met to Met/Met).  
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Comparisons of amphetamine sensitisation effects across species are complicated by several 
confounding factors, including differences in source of prefrontal dopaminergic innervation90, 91 
or cortical dopamine kinetics92.  Primates display reduced cortical dopamine turnover following 
chronic exposure to amphetamine30. although, it has been suggested that a transient period of 
hyper-responsivity of the ascending dopamine system precedes the decline seen with chronic 
use52. The cortical hyperactivity evident in our volunteers following brief exposure to 
amphetamine aligns with these suggestions. 
 
Unlike the cortical inefficiency observed by Mattay et al41, in addition to disrupting frontal and 
temporal activity, the hyperactivity seen, during the high-load condition, following sensitisation 
was evident throughout the associative fronto-striatal loop93, 94, similar to that seen in 
schizophrenia42. Given the role of striatal dopamine signalling in modulating cortico-striato-
thalamic activity, the hyperactivity of the caudate nucleus may be relevant for clarifying the 
origin of the concomitant observed frontal hyperactivity. In transgenic mice, Kellendonk et al.  
have shown that selective upregulation of striatal D2 dopamine receptors produced a prolonged 
prefrontal dysfunction in rodents which was maintained even after the transgene had been 
switched off and striatal D2 receptors had normalised95. This suggests that dysregulation of 
striatal D2 signalling can have a long-lasting deleterious effect on prefrontal development and 
functioning and that the prefrontal dysfunction evident in patients with schizophrenia, as well as 
sensitised animals, could arise from the dysregulation of striatal dopamine signalling. Such 
striatal dependency is also seen for the recruitment of the frontal lobes in patients with 
Parkinson’s disease. In this case frontal hypoactivity, linked to reduced striatal dopamine, is only 
evident when task performance necessitates the recruitment of the caudate nucleus82, 96, 97. In our 
study the higher load cognitive task demands greater manipulation of information and consequent 
caudate activation98. Thus, the striatal recruitment, combined presumably with elevated striatal 
dopamine, would be expected to elicit the observed hyperactivation of the prefrontal cortex.  This 
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would accord with the recent observations in patients with schizophrenia that dopamine depletion 
unmasks significantly more D2 receptors, indicating higher basal dopamine function, in the 
associative rather than limbic portion of the striatum99.  
 
Concerning the relation between neurophysiological consequences of amphetamine sensitisation 
and subjectively perceived state, we found that subjective measures of sensitisation-induced 
happiness were negatively correlated with striatal activity, while the DLPFC showed a positive 
correlation with subjective measures of alertness. The finding that subjective experience of 
sensitisation does not correlate with DLPFC activity, but sensitised alertness does, accords with 
the a role of the prefrontal cortex in mediating sensitisation-induced hypervigilance in primates 
and suggests negative striatal correlation suggests two separate neural substrates of sensitised 
behaviour.  
 
Our present findings on the effects of amphetamine sensitisation are of interest with regard to 
current pathophysiological theories of schizophrenia. Amphetamine has previously been shown to 
blunt striatal BOLD activity during the performance of a monetarily rewarded task100 which sits 
well with the absence of striatal activity change in the current study. A mechanism underlying 
this could be an enhancement of well established regulatory glutamatergic projections from the 
prefrontal cortex to the VTA101, 102, a critical pathway for sensitisation in rodents103. This 
enhanced prefrontal influence on VTA would result in an augmentation of activity in GABAergic 
interneurons in VTA, suppressing dopaminergic mesostriatal transmission. NMDA-dependent 
synaptic plasticity plays a central role in regulating the strength of the glutamatergic projections 
from DLPFC to VTA104, 105. Critically, this NMDA-dependent plasticity is modulated by 
dopamine itself, and this modulation has been proposed as a critical pathophysiological 
component in schizophrenia63. Furthermore, the interaction between D1 dopamine and NMDA 
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receptor signalling may play a vital role in determining the synaptic consequences of repeated 
stimulant exposure52, 106.   
 
Finally, the observed change in prefrontal activity during a high-load working memory challenge 
after only 4 intermittent low-dose exposures to amphetamine suggest that the recent rapid growth 
in the use of psychostimulants to boost alertness107 or to enhance cognitive performance108 may 
necessitate caution, especially given that sensitisation is still evident one year after cessation of 
the amphetamine64, and preliminary evidence demonstrating cross-sensitisation with stress 
following this dosage regimen109.  While our data might be expected to speak to the chronic use 
of stimulants to treat ADHD, the evidence for elevated risk of psychosis in these patients is 
scant110, especially considering the number of individuals using these drugs. It is likely that brain 
maturational processes in adolescents and the pattern of administration are not conducive to this 
form of neuroadaptation. In clinical practice sensitisation could offer one explanation for the 
relapsing nature of schizophrenia: while symptoms can be controlled by dopamine blocking 
antipsychotic medication, they are still sensitive to any stress induced perturbations. This may be 
because sensitised responses remains in place over a much longer period than the acute effects of 
the stimulant drugs. 
 
The primary limitations of this study are the relatively small sample size. Despite the small group 
size we found that sensitisation was associated with a significant change in fronto-striatal and 
temporal BOLD signal in accord with our hypotheses and consistent with the observed role of 
dopamine modulation of cognitive function. The addition of placebo scans either pre- or post-
sensitisation would have permitted a more powerful within-subjects test for the main effect of 
amphetamine (acute) and could permit us to assess whether sensitisation-related changes were in 
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evident without drug-administration, indicating altered cortical sensitivity at baseline.  However, 
the primary aims of this study was to assess whether the effects of amphetamine in a "sensitised-
brain" were different from acute exposure and the  repeated measures design ensured that we 
could test this directly. The degree to which sensitisation alters baseline (i.e. drug-free) brain 
function remains to be explored, although data suggests that sensitised volunteers also display an 
elevated placebo-induced dopamine release, consistent with a role for conditioning in the effects 
of sensitisation111. Finally, due to the small sample size we limited ourselves to testing our 
primary (core) hypotheses. With a larger sample size we could have carried out additional 
secondary examination of other interesting correlations with appropriate multiple comparisons 
correction. 
 
Conclusion 
To conclude, we presented here the first demonstration of amphetamine sensitisation-related 
changes in task performance and cortical functioning in healthy humans. As in non-human 
primates, striatal and cortical systems displayed separate, opposed, sensitisation profiles. We 
found similarities between the neural substrates of sensitisation-related changes in cognition in 
humans (e.g. hyperactivity of DLPFC, striatum and thalamus during a high-load WM challenge), 
and previous neuroimaging findings in patients with schizophrenia performing similar tasks. This 
implies that amphetamine sensitisation may be a useful model for investigating 
pathophysiological processes in schizophrenia and may help to bridge theories that emphasise 
pharmacological (dopaminergic) and cognitive mechanisms, respectively. 
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Figure Titles and Legends 
Figure.1: Subjective effects of amphetamine sensitisation. Group-by-session interaction for the 
subjective reports of amphetamine-like experience (top left), Session-by-hour measures of 
amphetamine-like effects in the amphetamine group (top right). The lower portion of this figure 
shows the significant correlation between the sensitisation of amphetamine-like experiences 
(difference between peak amphetamine-like experiences scores on sessions one and four) against 
the sensitisation of reaction-time. 
 
Figure. 2: The upper portion of this figure shows in red brain regions whose activity showed a 
main effect of  session (time) in the amphetamine group whereas those in yellow are regions 
showing a significant load-by-session interaction (for display purposes, results are shown at 
p<0.001 uncorrected, with a cluster threshold of 30 contiguous voxels). For visualisation of the 
nature of the interaction, the lower panel plots the parameter estimates extracted from the peak 
voxel in the right superior temporal gyrus [60, -9, 6]; this demonstrates a load-dependent failure 
of the normal suppression of the STG with increasing demands upon the working memory 
system.  
Figure. 3: The upper portion of this figure shows in red brain regions whose activity is elevated 
during the high-load condition following amphetamine sensitisation (p<0.05 whole-brain 
corrected at the cluster-level, with a voxel-level threshold of p<0.001). The lower panel shows the 
negative correlation between sensitisation of positive affect (VAMS Happy-Sad) and the change 
in striatal activation during the high WM challenge (left), and the positive correlation between 
sensitised alertness and the change in prefrontal activity during the high WM challenge 112.  
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Table1 
Amphetamine Main Effect of 
Time           
Region Label Side Size Z-Score x (mm) y(mm) z(mm) 
Sup.Temporal Gyrus 
(STG) R 338 4.35 60 -12 3 
Rol. Operculum R  4.21 60 0 9 
Insula R  3.81 39 3 9 
Precuneus R 31 3.87 12 -54 69 
Putamen L 30 3.83 -36 -9 3 
Fusiform R 53 3.63 36 -54 -21 
Cerebellum R  3.39 30 -54 -30 
Inf. Temporal R   3.31 48 -51 -18 
Amphetamine Load-by-Time Interaction         
Region Label Side Size Z-Score x (mm) y(mm) z(mm) 
Heschl's Gyrus R 158 4.22 60 -9 6 
Rol. Operculum R  4.17 63 3 15 
Precuneus R 39 3.97 9 -54 69 
 
Coordinates, statistics and labels for brain areas identified with a main effect of time (upper 
panel) and time-by-working memory load interaction in a 4x2 ANOVA (p<0.001 uncorrected, 30 
voxel cluster extent minimum for visualisation). BOLD signal changes, indicative of a main 
effect of time and a time-by-load interaction, within the superior temporal gyrus survived 
correction for multiple comparisons (p<0.05 FWE) within an anatomically defined ROI.  
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Table 2 
Amphetamine Paired t-test Session 4> Session 1 (High WM Load > 
Control)   
Region Label Side Size Z-Score x (mm) y(mm) z(mm) 
Precuneus L 226 4.26 -3 -75 42 
Precuneus R  3.79 3 -63 39 
STG/Operculum R 174 3.97 57 -12 12 
Putamen R  3.51 33 0 9 
Thalamus R 55 3.91 15 -6 15 
Caudate R  3.64 15 15 9 
Middle Frontal L 54 3.86 -33 0 51 
Superior Frontal L  3.65 -21 6 60 
Middle Frontal R 43 3.78 33 48 30 
 
Coordinates, statistics and labels for brain areas where BOLD signal during the high-load 
cognitive challenge, compared to the control condition, was significantly elevated  following 
sensitisation compared to acute amphetamine administration (maps presented are corrected for 
multiple comparisons on the basis of cluster extent at an uncorrected voxel threshold of p<0.001). 
BOLD signal increases in the DLPFC survived correction for multiple comparisons within an 
independently defined ROI.  
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Supp. Table 1: 
Placebo Main Effect Of Load         
Region Label Side Size  Z-Score x (mm) y(mm) z(mm) 
Inferior Parietal R 1095 7.54 45 -45 48 
Angular R  7.28 33 -63 48 
Middle Frontal L 3064 7.21 -27 0 51 
Precentral L  7.05 -45 3 33 
Superior Parietal L 637 6.96 -27 -69 57 
Angular L 87 6.24 -45 -66 27 
Calcarine L 456 6.22 -12 -63 15 
Posterior Cingulate L  6.07 -6 -51 24 
Superior Occipital R 91 5.84 18 -93 27 
Middle Occipital R  5.56 30 -93 18 
Insula L 180 5.73 -39 -21 21 
Middle Frontal L 97 5.71 -33 48 21 
Superior Occipital L 72 5.61 -15 -102 18 
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Inferior Frontal L 127 5.57 -39 15 6 
Putamen R 99 5.52 33 21 3 
Rolandic Operculum R 130 5.42 39 -18 18 
Caudate R 35 5.13 18 0 12 
Thalamus L 22 5.1 -12 -6 3 
Lingual R 44 5.09 12 -54 6 
Heschl R 29 5.07 60 -6 6 
Caudate L 13 4.99 -15 0 18 
Hippocampus L 5 4.83 -30 -6 -27 
Putamen R 2 4.62 39 -12 0 
 
Supp. Table 2. 
Amphetamine Main Effect of Load       
Region Label Side Size  Z-Score x (mm) y(mm) z(mm) 
Middle Frontal L 5293 7.71 -27 6 60 
SMA L  7.55 -3 3 60 
Middle Frontal R  7.52 42 33 30 
Precuneus R 2038 7.52 12 -72 57 
Inferior Parietal R  7.48 36 -54 45 
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Supermarginal R  7.25 42 -42 39 
Precuneus L 377 6.53 -6 -57 15 
Posterior Cingulate L  6.24 -3 -51 24 
Calcarine L  5.63 -9 -48 6 
Middle Frontal L 74 6.08 -39 48 21 
Cerebellum L 407 5.96 -42 -69 -30 
Cerebellum R  5.89 9 -75 -30 
Thalamus R 170 5.51 6 -9 9 
Inferior Temporal R 34 5.5 60 -51 -15 
Insula L 95 5.39 -36 18 -9 
Sup. Temporal Pole L  4.84 -54 12 -3 
Mid. Temporal Pole L 14 5.38 -39 18 -39 
Cerebellum R 42 5.37 33 -63 -33 
SMA L 35 5.35 0 -15 48 
Inferior Temporal R 10 4.98 60 -24 -21 
Parahippocampal L 11 4.96 -12 -27 -18 
Pallidum R 4 4.87 15 3 0 
Middle 
Orbitofrontal R 3 4.77 42 51 -12 
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Sup. Orbitofrontal L 5 4.75 -27 60 -6 
 


